Posters Archives - MaaT Pharma

Posters Scientific Publications

Restoration of gut microbiota diversity with oral pooled fecal microbiotherapy in acute myeloid leukemia patients after intensive chemotherapy: the phase 1b CIMON trial

MaaT PharmaDecember 11, 2022

Posters Scientific Publications

Pooled allogenic fecal microbiotherapy MaaT013 for the treatment of steroid-refractory gastrointestinal acute graft-versus-host disease: results from the phase IIa HERACLES study and expanded access program

MaaT PharmaNovember 13, 2022

Posters

Pooling of faecal material results in standardized and high-richness microbiotherapy products MaaT013 and MaaT033

MaaT PharmaNovember 13, 2022

Posters

Development of a culture manufacturing process preserving the profile of gut microbiota for therapeutic purposes

MaaT PharmaNovember 13, 2022

Posters

EBMT 2020: Successful and safe treatment of intestinal Graft-versus-Host Disease (GvHD) with pooled-donor full ecosystem microbiota therapeutics

MaaT PharmaAugust 31, 2020

Posters

ASH 2019: Successful and safe treatment of intestinal Graft-versus-Host Disease (GvHD) with pooled-donor full ecosystem microbiota therapeutics

nboutaouiDecember 7, 2019

Posters

An evaluation of binning methods to recover human gut microbial pan-genomes from non-redundant reference gene catalog

nboutaouiJuly 24, 2019

Posters

HERACLES: A Phase II single-arm prospective study to assess the efficacy of Fecal Microbiota Transfer (FMT) in the treatment of steroid-refractory gastro-intestinal predominant aGVHD post allo-hsct

nboutaouiMarch 26, 2019

Posters

ASH 2018: The Odyssee study: Results of a prospective multicenter trial

nboutaouiDecember 2, 2018

Posters

EMBL: Developing a New Generation of First-in-class High Diversity Microbiome Biotherapeutics to Treat Life-threatening Diseases

MaaT PharmaSeptember 18, 2018

© 2023 MaaT Pharma. MaaT Pharma’s mission is to restore microbiome function to treat life-threatening diseases

MaaT Pharma dans les médias MaaT Pharma in the News